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Abstract: Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint
infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant
removal (IRm) or debridement and retention (DAIR). To analyze the outcomes of all cases managed
Antibiotics 2021, 10, 118. https://doi.org/10.3390/antibiotics10020118 https://www.mdpi.com/journal/antibiotics
Antibiotics 2021, 10, 118 2 of 13
with IRm (initially or after DAIR failure). Methods: Retrospective, multicenter, cohort study of PJI by
S. aureus (2003–2010). Overall failure included mortality within 60 days since surgery and local failure
due to staphylococcal persistence/relapse. Results: 499 cases, 338 initially managed with DAIR, 161
with IRm. Mortality was higher in acute PJI managed initially with IRm compared to DAIR, but
not associated with the surgical procedure, after propensity score matching. Underlying conditions,
hemiarthroplasty, and methicillin-resistant S. aureus were risk factors for mortality. Finally, 249 cases
underwent IRm (88 after DAIR failure); overall failure was 15.6%. Local failure (9.3%) was slightly
higher in cases with several comorbidities, but independent of previous DAIR, type of IRm, and
rifampin treatment. Conclusions: In a large multicenter study of S. aureus PJI managed with IRm,
failure was low, but mortality significant, especially in cases with acute PJI and underlying conditions,
but not associated with the IRm itself. Rifampin efficacy was limited in this setting.
Keywords: Staphylococcus aureus; prosthetic joint infection; implant removal; outcome; rifampin
1. Introduction
Prosthetic joint infection (PJI) is a serious complication after joint replacement [1].
Staphylococcus aureus represents almost a third of all episodes [2], mostly associated with
acute PJI (early post-surgical and hematogenous infections) [3], but also with chronic
post-surgical infections.
Surgery is central for the optimal management of PJI by S. aureus, with two main
strategies: debridement, antibiotics, and implant retention (DAIR), or implant removal
(IRm) [3,4]. Observational studies have analyzed the outcome of DAIR [5–9], but the
prognosis of IRm, generally performed in chronic PJI or after DAIR failure, has not been
extensively evaluated [10,11]. Some authors have suggested that IRm as salvage therapy
may lead to poorer outcomes compared with an initial management with IRm [12,13]. The
role of rifampin is not formally established, contrasting with its benefits in DAIR [8,14].
Previously, the prognosis of the largest case-series of staphylococcal PJI managed with
DAIR was analyzed [8]. However, the characteristics and outcome of cases treated with
IRm were not reported in that analysis.
Therefore, our aim was to revise this large multicenter study with the objectives
of (i) analyzing the subcohort of cases with acute PJI to compare the characteristics and
outcomes of those initially managed with IRm or DAIR; and (ii) evaluating the outcomes
of the subgroup of all cases managed with IRm, initially or as salvage therapy after DAIR
failure including the role of rifampin.
2. Results
During the study period, 561 cases were initially identified to have PJI by S. aureus,
but 62 cases had exclusion criteria. Thus, 499 cases were finally included: 325 (65.1%) with
early post-surgical (EA) PJI, 75 (15.0%) with hematogenous PJI, and 99 (19.8%) with chronic
post-surgical PJI.
Follow-up data (median 781 days, interquartile range [IQR] 355-1375) and/or known
outcomes were available for 478 cases. Figure 1 shows the percentage of cases with overall
failure (local failure plus mortality), local failure, and mortality in all cases and according
to the type of PJI.
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Figure 1. Outcomes of cases with prosthetic joint infection (PJI) by Staphylococcus aureus according to the type of infection. 
*p value < 0.01 in overall and local failure between hematogenous, early post-surgical, and chronic post-surgical PJI; **p 
value = 0.201 in mortality between hematogenous, early post-surgical, and chronic post-surgical PJI. 
2.1. Implant Removal as the Initial Surgical Strategy in the Cohort of Acute Prosthetic Joint In-
fection (PJI) 
Similar differences in characteristics between cases managed with IRm and DAIR 
were found in EA and hematogenous PJI, which were therefore analyzed together as acute 
PJI (n = 400, Table 1). Cases with acute PJI managed with IRm were more likely to have a 
hemiarthroplasty or hematogenous PJI, but also other factors such as abnormal radiog-
raphy, symptoms duration >21 days, poor condition of soft tissues, or infection by MRSA. 
Table 1. Characteristics, adjusted odds ratios of implant removal and outcome of 400 cases of acute prosthetic joint infec-
tion (early post-surgical and hematogenous) by Staphylococcus aureus, according to their initial surgical management. 
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Female sex 184 (59.2) 59 (66.3) 0.225   
Age (years) 1 72 (64–78) 74 (68–78) 0.168 1.01 (0.99–1.04) 0.294 
Two or more comorbidi-
ties 2 60 (19.3) 17 (19.1) 0.968   
Chronic kidney disease 16 (5.1) 8 (9.0) 0.178   
PROSTHESIS CHARAC-
TERISTICS 
     
Total hip arthroplasty 109 (35.1) 27 (30.3) 0.408   
Total knee arthroplasty 174 (56.0) 45 (50.6) 0.368   
Hemiarthroplasty 24 (7.7) 14 (15.7) 0.023 3.73 (1.60–8.68) 0.003 
Revision prosthesis 53 (17.0) 14 (15.7) 0.770   
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2.1. Implant Removal as the Initial Surgical Strategy in the Cohort of Acute Prosthetic Joint
Infection (PJI)
Similar differences in characteristics between cases managed with IRm and DAIR
were found in EA and hematogenous PJI, which were therefore analyzed together as
acute PJI (n = 400, Table 1). Cases with acute PJI managed with IRm were more likely to
have a hemiarthroplasty or hematogenous PJI, but also other factors such as abnormal
radiography, symptoms duration >21 days, poor condition of soft tissues, or infection by
MRSA.
Table 1. Characteristics, adjusted odds ratios of implant removal and outcome of 400 cases of acute prosthetic joint infection















Female sex 184 (59.2) 59 (66.3) 0.225
Age (years) 1 72 (64–78) 74 (68–78) 0.168 1.01 (0.99–1.04) 0.294
Two or more
comorbidities 2 60 (19.3) 17 (19.1) 0.968
C i kidney disease 16 (5.1) 8 (9.0) 0.178
PROSTHESIS
CHARACTERISTICS
Total hip arthroplasty 109 (35.1) 27 (30.3) 0.408
Total knee arthroplasty 174 (56.0) 45 (50.6) 0.368
Hemiarthroplasty 24 (7.7) 14 (15.7) 0.023 3.73 (1.60–8.68) 0.003
Revision prosthesis 53 (17.0) 14 (15.7) 0.770
















Hematogenous PJI 49 (15.8) 26 (29.2) 0.004 3.34 (1.72–6.46) <0.001
Leukocytosis 3 157 (50.5) 52 (58.4) 0.186
CRP (mg/L) 109 (28–120) 100 (30–107) 0.415
Abnormal radiography 4 27 (8.7) 26 (29.2) <0.001 3.70 (1.85–7.43) <0.001
Duration of symptoms
>21 days 33 (10.6) 37 (41.6) <0.001 7.69 (4.03–14.68) <0.001
Poor condition of soft
tissues 37 (11.9) 19 (21.4) 0.023 1.50 (0.72–3.12) 0.282
Infection by MRSA 75 (24.1) 34 (38.2) 0.008 1.42 (0.95–3.19) 0.074
Bacteremia 57 (18.3) 17 (19.1) 0.868
Polymicrobial infection 58 (18.7) 19 (21.4) 0.569
OUTCOME 5
Overall failure 107 (35.7) 20 (23.3) 0.031
Local failure 94 (31.3) 9 (10.5) <0.001
Mortality <60 days 13 (4.3) 11 (12.8) 0.004
Categorical variables expressed in absolute number and (percentage); continuous variables expressed in median and (interquartile range).
PJI: Prosthetic joint infection. DAIR: Debridement, antibiotics and implant retention. OR: Odds ratio. 95%CI: 95% Confidence Interval. IQR:
Interquartile range. MRSA: Methicillin-resistant S. aureus. * Refers to a multivariate analysis of factors associated with implant removal
in patients with acute PJI (n = 400). 1 Odds ratio expressed as per year. 2 These include severe comorbidities (diabetes, liver cirrhosis,
chronic kidney disease, immunosuppressive treatment, rheumatoid arthritis, malignancy, chronic lung, and heart diseases) present in
the McPherson Staging System [15]. 3 Leukocytosis is defined as baseline leukocyte count above 10 × 109/L. 4 Abnormal radiography
is defined according to radiologic signs of infection (loosening, periprosthetic osteolysis, migration, subperiostic reaction). 5 Calculated
among 300 patients with acute PJI managed with DAIR and 86 patients with acute PJI managed with implant removal.
Mortality was greater in acute PJI managed initially with IRm compared to DAIR.
However, after performing propensity score matching including several pre-surgical vari-
ables (age, number of comorbidities, hemiarthroplasty, hematogenous PJI, abnormal radio-
graphy, symptoms duration, condition of soft tissues, infection by MRSA and hospital),
mortality was not associated with the IRm procedure itself (OR 1.55; 95%CI 0.47–4.56;
p = 0.387) (Figure S1A).
Among cases with acute PJI initially managed with IRm (Figure 2), mortality was
greater if they had two or more comorbidities (7/16 [43.8%] vs. 4/70 [5.7%]; p < 0.001),
especially rheumatoid arthritis (3/7 [42.9%] vs. 8/79 [10.1%]; p = 0.042) and immunosup-
pressive treatment (4/7 [57.1%] vs. 7/79 [8.9%]; p = 0.004). Mortality was also higher if they
had a hemiarthroplasty (5/14 [35.7%] vs. 6/72 [8.3%]; p = 0.015), bacteremia (5/9 [55.6%]
vs 6/77 [7.8%]; p = 0.001), and infection by MRSA (8/32 [25.0%] vs. 3/54 [5.6%]; p = 0.016).
2.2. Cohort of All Cases Managed with Implant Removal (Initially or Salvage Therapy)
Together with 161 cases managed initially with IRm (63, 26, and 72 with EA, hematoge-
nous and chronic post-surgical PJI, respectively), there were 88 cases (78 with acute and
10 with chronic post-surgical PJI) who finally underwent IRm as salvage therapy. Thus,
this procedure was performed in 249 cases (Table 2): two-stage exchange (188, 75.5%),
hip resection arthroplasty (44, 17.7%), and one-stage exchange (17, 6.8%). No significant
differences were found in surgical strategies between clinical groups (p = 0.440). There
were 52 cases (27.7%) under the two-stage scheme without a second stage performed;
thus, 96 cases (38.6%) finally had resection arthroplasty, who more often had two or more
comorbidities (26.0% vs. 16.3%; p = 0.063).
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Table 2. Characteristics and outcome of the subcohort of cases of prosthetic joint infection by Staphylococcus aureus managed
with implant removal (n = 249), according to their type of infection.
Acute PJI (Early Post-Surgical
















Female sex 59 (66.3) 52 (66.7) 0.959 46 (63.9) 7 (70.0) 0.705
Age (years) 74 (68–78) 72 (60–79) 0.470 74 (64–79) 68 (57–76) 0.082
Two or more
comorbidities 1 17 (19.1) 16 (20.5) 0.819 13 (18.1) 4 (40.0) 0.109
Chronic kidney disease 8 (9.0) 6 (7.7) 0.763 8 (11.1) 0 0.267
Hemiarthroplasty 14 (15.7) 3 (3.9) 0.011 3 (4.2) 0 0.511
Revision prosthesis 14 (15.7) 18 (23.1) 0.229 15 (20.8) 5 (50.0) 0.044
Infection by MRSA 34 (38.2) 16 (20.5) 0.013 12 (16.7) 3 (30.0) 0.307
Bacteremia 9 (10.1) 4 (5.1) 0.230 1 (1.4) 0 0.708
Polymicrobial infection 19 (21.4) 20 (25.6) 0.513 20 (27.8) 2 (20.0) 0.603
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Table 2. Cont.
Acute PJI (Early Post-Surgical

















Overall failure 20 (23.3) 9 (12.0) 0.064 6 (9.0) 2 (22.2) 0.223
Local failure 9 (10.5) 7 (9.3) 0.811 4 (6.0) 2 (22.2) 0.090
Mortality < 60 days 11 (12.8) 2 (2.7) 0.019 2 (3.0) 0 0.599
Categorical variables expressed in absolute number and (percentage); continuous variables expressed in median and (interquartile range).
IRm as salvage therapy refer to cases who failed after an initial management with DAIR (Debridement, antibiotics, and implant retention).
PJI: Prosthetic joint infection. IRm: Implant removal. MRSA: Methicillin-resistant S. aureus. * Comparison between acute PJI. ** Comparison
between chronic PJI. 1 These include severe comorbidities (diabetes, liver cirrhosis, chronic kidney disease, immunosuppressive treatment,
rheumatoid arthritis, malignancy, chronic lung and heart diseases) present in the McPherson Staging System [15]. 2 Calculated among
86 patients with acute PJI initially managed with implant removal, 75 patients with acute PJI initially managed with DAIR, 67 patients with
chronic PJI initially managed with implant removal, and nine patients with chronic PJI initially managed with DAIR.
The median length of antimicrobial therapy was 59 days (IQR 43–92). There were
119 cases (55.4%) who received rifampin in combination during ≥21 days in the first 42 days
after IRm. Other antibiotics commonly given, either alone or in combination with rifampin,
were quinolones (43.3%), beta-lactams (28.8%), cotrimoxazole (16.3%), and glycopeptides
(11.6%).
Overall, 237 cases had outcome data, of whom 37 (15.6%; 95%CI 11.2–20.9) presented
overall failure, 22 (9.3%; 95%CI 5.9–13.7) local failure, and 15 patients died (6.3%; 95%CI
3.6–10.2). Mortality occurred to 11 patients (12.8%) with acute PJI initially managed with
IRm, two (2.7%) with acute PJI requiring IRm as salvage therapy and two (3.0%) with
chronic post-surgical PJI initially managed with IRm.
Local failure was similar in all IRm strategies, but slightly higher (22.2%) in those with
chronic PJI initially managed with DAIR (Table 2). In an analysis of predictive factors of
local failure (Table 3), having two or more comorbidities showed a trend toward greater
local failure, whereas cases requiring IRm as salvage therapy after DAIR failure did not
present worse outcomes. Cases receiving rifampin for 21 days or longer within the first
42 days did not present lower rates of local failure (10.1% vs. 7.3%; p = 0.473). Similar results
(HR 0.82; 95%CI 0.39–1.70; p = 0.590) were found when estimating the effect of rifampin
≥ 21 days after propensity score matching (including age, number of comorbidities, liver
cirrhosis, type of infection, infection by MRSA, previous DAIR, type of IRm, and hospital;
Figure S1B).
Table 3. Predictive factors of local failure among 237 cases of prosthetic joint infection by Staphylococcus aureus managed
with implant removal (22 cases failed).
Characteristic Failed/Total (%) Crude HR(95%CI) p Value
Adjusted HR
(95% CI) p Value
Age <75 years 15/127 (11.8) 1 1
≥75 years 7/110 (6.4) 0.59 (0.24–1.44) 0.234 0.59 (0.24–1.44) 0.231
Sex Male 9/80 (11.3) 1
Female 13/157 (8.3) 0.67 (0.29–1.57) 0.364
Two or more comorbidities 1 No 15/192 (7.8) 1 1
Yes 7/45 (15.6) 2.44 (0.99–5.99) 0.051 2.46 (1.00–6.09) 0.051
Hemiarthroplasty No 21/218 (9.6) 1
Yes 1/19 (5.3) 0.87 (0.12–6.50) 0.891
Revision prosthesis No 15/185 (8.1) 1
Yes 7/52 (13.5) 1.77 (0.72–4.37) 0.232
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Table 3. Cont.
Characteristic Failed/Total (%) Crude HR(95%CI) p Value
Adjusted HR
(95% CI) p Value
Hematogenous PJI No 18/193 (9.3) 1
Yes 4/44 (9.1) 0.93 (0.31–2.75) 0.891
Infection by MRSA No 18/179 (10.1) 1
Yes 4/58 (6.9) 0.87 (0.29–2.57) 0.798
Bacteremia No 21/223 (9.4) 1
Yes 1/14 (7.1) 1.76(0.23–13.32) 0.613
Polymicrobial infection No 19/178 (10.7) 1
Yes 3/59 (5.1) 0.51 (0.15–1.71) 0.236
Initially managed with DAIR No 13/153 (8.5) 1 1
Yes 9/84 (10.7) 1.06 (0.45–2.49) 0.886 0.94 (0.40–2.23) 0.897
Surgical management One-stageexchange 2/16 (12.5) 1
Two-stage
exchange 16/182 (8.8) 0.60 (0.14–2.62)
Hip resection
arthroplasty 4/39 (10.3) 0.84 (0.15–4.61) 0.720
Rifampin 2 No 7/96 (7.3) 1
Yes 12/119 (10.1) 1.01 (0.37–2.73) 0.989
HR: Hazard ratio. 95% CI: 95% Confidence interval. PJI: Prosthetic joint infection. MRSA: Methicillin-resistant S. aureus. DAIR:
Debridement, antibiotics, and implant retention. 1 These include severe comorbidities (diabetes, liver cirrhosis, chronic kidney disease,
immunosuppressive treatment, rheumatoid arthritis, malignancy, chronic lung and heart diseases) present in the McPherson Staging
System [15]. 2 Among those treated with rifampin for 21 days or longer in the initial 42 days since implant removal.
Among the cases with local failure, nine presented symptomatic persistence of infec-
tion, eight relapsed, and five presented positive cultures in a second-stage exchange. There
were 16 cases with positive staphylococcal cultures upon failure, but none were rifampin-
resistant. Long-term follow-up was available in 19/22 cases; four needed long-term SAT,
while the rest eventually were considered cured after further treatment.
3. Discussion
PJI by S. aureus represents a therapeutic challenge for physicians. While most of the
knowledge on its outcome involves patients managed with DAIR [5–9], IRm has received
scarce attention in the literature [10,11]. To the best of our knowledge, the present study
includes the largest series of cases with S. aureus PJI managed with IRm.
The selection of patients with acute PJI (early post-surgical or hematogenous PJI) to
be managed either with DAIR or IRm usually follows well-known algorithms such as
the standardized Zimmerli criteria [3], which do not include host conditions but factors
related to symptom duration, the condition of the implant and soft tissues, and anti-biofilm
antimicrobial susceptibility. Additionally, there is still controversy whether DAIR should
be performed in infections within 30–90 days since arthroplasty. In this study, among cases
with acute PJI, those with hemiarthroplasty, hematogenous PJI, and/or infection by MRSA
were more likely to be managed with IRm.
In this line, previous studies found higher failure rates in patients managed with DAIR
who presented these characteristics [8,16] as well as those with particular comorbidities,
suggesting that Zimmerli criteria may be revisited. Some authors have attempted to
build scores such as the KLIC score [16,17], which may provide guidance in selecting the
optimal surgical management for patients with acute PJI. Similarly, the McPherson staging
system [15], which includes host factors, has been correlated with the outcome of acute
and chronic PJI [18,19] and may define the optimal surgical strategy for each patient [20].
However, these scores were built from studies that include heterogeneous patients with
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diverse causative microorganisms and have shown poor prediction in staphylococcal PJI.
Overall, it seems plausible that future research should address the development of specific
scores for S. aureus PJI. Additionally, the surgeon’s and/or patient’s preferences should
also be considered.
Mortality was higher in patients with acute PJI managed with IRm compared to those
undergoing DAIR. Importantly, the surgical procedure was not associated with the higher
mortality observed after propensity score matching. Interestingly, the same characteristics
(hemiarthroplasty, MRSA) that were driving IRm in acute PJI were also associated with
a greater probability of mortality. While some characteristics such as hemiarthroplasty
and/or MRSA have been previously recognized as risk factors for mortality [21,22], the
results suggest that patients with several underlying conditions also have greater likeli-
hood of mortality, especially if bacteremic [23]. Importantly, these factors may present
together [22] and, therefore, physicians should rapidly identify and provide accurate care
of older patients, with hemiarthroplasties and/or infections by MRSA when managing
acute staphylococcal PJI.
IRm was associated with low local failure. Obviously, the physical removal of biofilm
facilitates the activity of antimicrobials, resulting in a greater chance of cure, compared
to DAIR [24,25]. However, even in this favorable situation, some patients failed. Salvage
therapy eventually cured most patients, suggesting a good overall prognosis when a first
procedure is unsuccessful.
Most factors associated with mortality did not influence the likelihood of local failure,
but cases with several comorbidities had slightly higher local failure [15]. Interestingly,
the outcome was not worse in patients who needed IRm as salvage therapy, suggesting
that DAIR can be attempted without affecting the prospects for a future removal surgery, if
needed. This study, though, could not evaluate whether an initial DAIR might affect the
functional outcome of patients needing IRm, which has aroused some controversy in the
literature [12]. Failure rates were similar according to IRm strategies including one-stage
exchange, as reported also by Senneville et al. [11]. However, since the vast majority of our
patients were managed with two-stage exchange, more data are needed to evaluate the
outcome of other strategies with larger sample sizes.
The role of rifampin following IRm is not well established, in contrast with staphy-
lococcal PJI managed with DAIR. In a short series evaluating cases managed with DAIR
or IRm [11], Senneville et al. reported better results in patients receiving rifampin, but
unfortunately, the authors did not provide a thorough analysis of cases managed with
IRm. In this study, a better outcome in patients treated with rifampin during more than
21 days could not be proven. The design of this study did not allow us to draw definitive
conclusions on the benefits of rifampin in this setting and further research should address
this clinical question.
Several limitations are inherent to the observational retrospective study design, de-
spite being multicentric and its large sample size. Patients included were potentially
heterogeneous in their characteristics, presentations, and management, which may have
underpowered some analyses. Matching and multivariate analyses have been performed to
adjust for this variability, but possible biases and imbalances may still have occurred. Local
failure was evaluated based solely on persistence/relapse of S. aureus; thus, higher failure
rates may have been found if other criteria such as superinfections or orthopedic problems
had been included. Finally, not only monomicrobial PJIs by S. aureus were included, but
also polymicrobial infections. However, we believe that the present data offer an overall
perspective of the prognosis of PJI by S. aureus.
4. Materials and Methods
4.1. Design, Setting, and Patients
This was a retrospective, multicenter cohort study performed in 17 hospitals in Spain,
in the framework of the Spanish Network for Research in Infectious Diseases (REIPI) during
2003–2010, which included all consecutive cases of PJI caused by S. aureus identified from
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previously registered databases or from the general archives in each hospital. Two cohorts
were analyzed: (i) the subcohort of acute PJI was used to compare the characteristics and
outcomes of cases managed initially with IRm or DAIR; and (ii) the subcohort of all cases
managed with IRm, either initially or as salvage therapy after DAIR failure, was used to
investigate their outcome (mortality and factors predicting failure).
Cases of PJI caused by S. aureus, monomicrobial or polymicrobial, managed with
DAIR or IRm were included. Cases where S. aureus did not cause the original PJI, but
participated later as a superinfecting microorganism, those requiring amputation as the
initial surgical procedure for IRm, and those catalogued as positive intraoperative cultures
according to Tsukayama’s criteria [26] were excluded. Patient consent was not required,
given the retrospective design; data were anonymized, without sensitive information that
may enable the participant’s identification.
4.2. Definitions
PJI was defined according to Infectious Diseases Society of America guidelines and
microorganisms were identified according to standard criteria [3,4,8,27]. In accordance with
the most commonly used classifications of types of PJI, these were categorized into early
post-surgical (EA), chronic post-surgical, and acute hematogenous. The latter included
cases with ≤3 weeks of symptoms duration appearing three months after surgery in the
setting of microbiologically confirmed or clinically suspected staphylococcal bacteremia.
Regarding EA and chronic post-surgical PJI, there is still controversy on definitions based
on time from arthroplasty and accordingly, EA-PJI may include cases that present within
one month or three months [3,4,26,28,29], and these time cut-offs are usually employed
in selecting patients to be managed successfully with DAIR. Thus, for the purpose of this
study, PJI occurring within three months after prosthesis placement were classified as EA,
whereas defined as chronic post-surgical, if these started thereafter [3,4]. When analyzing
the subcohort of acute PJI, EA and acute hematogenous PJI were included.
Baseline characteristics were recorded and included severe comorbidities (diabetes,
liver cirrhosis, chronic kidney disease (CKD), immunosuppressive treatment, rheumatoid
arthritis, malignancy, chronic lung, and heart diseases) present in the McPherson Staging
System [15].
4.3. Clinical and Surgical Management
The decision to manage patients with DAIR or IRm was taken by the attending medical
team, commonly following Zimmerli’s criteria [3]; patients with duration of symptoms
≤21 days, a stable implant, and appropriate soft tissues condition usually qualify for DAIR.
Regarding the controversies in definitions of EA PJI above-mentioned, infections occurring
within 30–90 days since prosthesis placement were usually considered for IRm, but might
have also been managed with DAIR.
DAIR management, which was performed only as an initial strategy, has been de-
scribed elsewhere [7,8]. IRm was performed as an initial strategy or after DAIR in patients
who failed. IRm was classified into three surgical approaches [30]: (a) two-stage exchange;
(b) one-stage exchange; and (c) hip resection arthroplasty. Cases were considered under the
two-stage exchange scheme if the intention was to implant a new prosthesis or arthrodesis,
irrespective of whether this second stage was finally performed.
In most hospitals, the usual perioperative antimicrobial prophylaxis for arthroplasties
consists of intravenous cefazolin 2 g. After the surgical procedure for PJI, intravenous
antibiotics of wide antimicrobial-spectrum are administered. Once the antimicrobial sus-
ceptibility is available, antibiotics are adjusted according to current guidelines. However,
the ultimate choice of the antimicrobial treatment is at the discretion of the medical team.
The intravenous route is maintained for a variable period depending on each hospital
protocol, usually followed by oral antibiotics, also for a variable time.
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4.4. Outcomes and Follow-Up
Patients were followed until death, failure, or loss to follow-up. Overall failure was
defined as a composite endpoint consisting of local failure and/or mortality due to any
cause occurring within 60 days since surgery (cut-off selected to reflect mortality potentially
linked to the PJI process).
In cases managed with DAIR, local failure has been defined elsewhere [8], but only
considered if related to staphylococcal persistence/relapse. In cases managed with IRm, it
was defined also only if staphylococcal persistence/relapse as: (a) symptom persistence
beginning within 30 days after IRm, leading to long-term suppressive antimicrobial therapy
(SAT) and/or new surgeries, irrespective of when these were performed; (b) relapsing
symptoms in asymptomatic patients initially considered cured after IRm; and (c) positive
S. aureus cultures in asymptomatic patients undergoing a second-stage surgery.
4.5. Statistical Analysis
Data were analyzed with Stata 13.1 (Stata Corporation, USA). Categorical and contin-
uous variables were described by counts and percentages, and median and interquartile
range (IQR), respectively. Comparisons between groups were performed with the chi-
square test or Fisher exact test for categorical variables and the t-test or Mann–Whitney
test for continuous variables.
Multivariate logistic regression was used to analyze factors associated with initial
management with IRm in acute PJI including the commonly used Zimmerli’s criteria [3].
Kaplan–Meier survival curves were used to evaluate the probability of success during
follow-up and the log-rank test analyzed differences between groups, censoring cases lost
to follow-up. Multivariate Cox regression was performed to estimate factors associated
with local failure, censoring death as a competing event.
To evaluate the impact of interventions (surgical procedure [DAIR vs. IRm] and
rifampin) on mortality and local failure, respectively, propensity score matching analyses
were performed. Clinically relevant variables were introduced in the propensity model,
together with baseline characteristics found to have a univariate association with the
intervention (p < 0.1). The adequacy of the models was assessed with calibration plots and
the Hosmer–Lemeshow test. Nearest neighbor matching with replacement was performed
with 0.1 calipers. Mean standardized differences for covariates between matched groups
were checked prior to treatment effects estimation.
The length of antibiotic therapy could be shortened in cases failing prematurely and
would not actually be the cause of failure but its consequence. Thus, in order to avoid
survivor’s bias, the influence of rifampin on local failure was only analyzed in cases treated
for ≥21 days and not requiring salvage surgeries within the first 42 days after IRm.
5. Conclusions
In conclusion, while mortality was significant in acute PJI by S. aureus managed with
IRm, there was no evident association with the surgical approach itself. Additionally, we
identified factors related to the patient’s condition that were associated with a greater
probability of death among these cases. Local failure was low, but a previous DAIR strategy
did not worsen the outcome of cases. Despite the limited efficacy found in this study,
further research should confirm whether rifampin may still offer a potential benefit in the
treatment of patients with staphylococcal PJI managed with IRm.
Supplementary Materials: The following are available online at https://www.mdpi.com/2079-6
382/10/2/118/s1, Figure S1: Standardized bias for covariates before and after propensity score
matching for the evaluation of implant removal on mortality in cases with acute prosthetic joint
infection by Staphylococcus aureus (A) and the role of rifampin on local failure in all cases managed
with implant removal (B).
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